A phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of adjuvant giredestrant

Full title: A phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of adjuvant giredestrant compared with physician's choice of adjuvant endocrine monotherapy in patients with estrogen receptor−positive, her2-negative early breast cancer